Showing results (601-610 of 746) with videos related to

Sort By:
Pageof 75
International Journal of Environmental Research and Public Health|March 29, 2023
Quality of Life in Patients with Pancreatic Cancer-A Literature ReviewElżbieta Cipora, Aleksandra Czerw, Olga Partyka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2025
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/<i>TP53</i> Mutation: SEQUOIA Arm D ResultsMazyar Shadman, Talha Munir, Shuo Ma, et al.
Cell Death & Disease|October 21, 2025
ZC3H4, a novel regulator of mitochondrial complex I, impacts prostate stromal cell senescence, attachment, adhesion and anoikis resistanceTeresa T Liu, Mia J Carrarini, Livianna K Myklebust, et al.
Nature|February 3, 2012
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesityJorge Henao-Mejia, Eran Elinav, Chengcheng Jin, et al.
Hemasphere|November 18, 2022
Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial ResultsPaolo Ghia, Andrzej Pluta, Małgorzata Wach, et al.
Future Oncology (London, England)|November 15, 2022
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphomaToby A Eyre, Nirav N Shah, Martin Dreyling, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 25, 2025
A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic MalignanciesMichal Kwiatek, Guru Subramanian Guru Murthy, Marc Hoffmann, et al.
Diabetologia|April 11, 2014
Muscle-specific activation of Ca(2+)/calmodulin-dependent protein kinase IV increases whole-body insulin action in miceHui-Young Lee, Arijeet K Gattu, João-Paulo G Camporez, et al.
Nature Chemical Biology|January 26, 2021
A Fbxo48 inhibitor prevents pAMPKα degradation and ameliorates insulin resistanceYuan Liu, Michael J Jurczak, Travis B Lear, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2020
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaPaolo Ghia, Andrzej Pluta, Malgorzata Wach, et al.
Pageof 75